NEODOSE

INDICATIONS

• Decolonization: Along with other infection control processes in a neonatal intensive care unit (NICU), mupirocin decolonization may be used during outbreaks of Staphylococcus aureus and in the management of colonized neonates at high risk for S aureus infection. In a retrospective cohort study in a single-institution NICU (with low-level endemic MRSA), 22% (95% CI 4% to 37%) of MRSA acquisition could be attributed to MRSA carriers who were untreated . Decolonization, which included intranasal mupirocin, of MRSA-colonized neonates (n=522) decreased the risk of gram-positive infections with no increased risk ofgram-negative infection in a multicenter, retrospective NICU study.
• Cutaneous Infections: Topical use for skin infections caused by Staphylococcus aureus, S epidermidis, S saprophyticus, and Streptococcus pyogenes.

CONTRAINDICATION/PRECAUTION

• Use of Bactroban(R) ointment is not recommended with conditions in which absorption of large quantities of polyethylene glycol may occur, particularly in the presence of moderate or severe renal impairment.
• Bactroban(R) ointment and cream are not for use on mucosal surfaces.
• Discontinue use if sensitization or severe local irritation occur.
• Avoid contact with eyes and rinse thoroughly if accidental contact occurs .
• Systemic allergic reactions, which may be severe, have been reported, including anaphylaxis, urticaria, angioedema, and rash .
• Overgrowth of nonsusceptible organisms, including fungi, may occur with prolonged use. Clostridium difficile-associated diarrhea has been reported; evaluate and institute appropriate medical management if suspected or confirmed. Discontinuation may be warranted.
• Avoid use of mupirocin nasal ointment with other intranasal products.

MONITORING

Assess affected area for continued infection.

ADVERSE EFFECTS

Use only on the skin. No adverse effects reported from topical administration. Routine use may lead to selective bacterial resistance.